Ecoguided Genicular Nerve Block

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

January 2, 2024

Study Completion Date

November 2, 2024

Conditions
Osteoarthritis, Knee/Rehabilitation
Interventions
DRUG

Genicular nerve block with bupivacaine and corticosteroids

"\- GROUP 1:Genicular Nerve Block with Bupivacaine and Corticosteroids: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."

DRUG

Genicular nerve block with bupivacaine

"\- GROUP 2: Genicular Nerve Block with Bupivacaine: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."

DRUG

Genicular nerve block with saline

"\- GROUP 3: Genicular Nerve Block with Saline: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."

Trial Locations (1)

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

All Listed Sponsors
lead

Hospital Universitario Fundación Alcorcón

OTHER